Περίληψη:
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14–104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p < 0.001) and need for hospitalization (p < 0.001) correlated with higher antibody titers, while asymptomatic status (p < 0.001) and testing >60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Terpos, E.
Politou, M.
Sergentanis, T.N.
Mentis, A.
Rosati, M.
Stellas, D.
Bear, J.
Hu, X.
Felber, B.K.
Pappa, V.
Pagoni, M.
Grouzi, E.
Labropoulou, S.
Charitaki, I.
Ntanasis-Stathopoulos, I.
Moschandreou, D.
Bouhla, A.
Saridakis, S.
Korompoki, E.
Giatra, C.
Bagratuni, T.
Pefanis, A.
Papageorgiou, S.
Spyridonidis, A.
Antoniadou, A.
Kotanidou, A.
Syrigos, K.
Stamoulis, K.
Panayiotakopoulos, G.
Tsiodras, S.
Alexopoulos, L.
Dimopoulos, M.A.
Pavlakis, G.N.
